Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Inclusion Criteria: * Target and Period: Patients aged 18 or older * Target Conditions: 1. Lazertinib: * Patients diagnosed with locally progressive or metastatic non-small cell lung cancer, who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period * Patients with T790M mutation positive * Patients with an ECOG PS score of 0 to 1 at the time of initial drug administration 2. Platinum-based Chemotherapy * Patients who were diagnosed with locally advanced or metastatic non-small cell lung cancer, and previously received first or second-generation EGFR-TKI treatment during the baseline period * Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period * Patients who were confirmed positive for active EGFR mutations (L858R, Exon19Del, G719X, L861Q) during the baseline period * Patients with an ECOG PS score of 0 to 1 at the time of initial drug administration Exclusion Criteria: * Patients with carcinoma besides NSCLC requiring treatment * Any unstable brain metastasis with symptomatic and/or requiring emergency treatment